Street traffic academy to expand statewide, making roads safer for everyone
Large colored barriers and street murals sit at the intersection of Virginia Ave and S College Ave to reduce serious traffic crashes and fatalities. (Madelyn Hanes/Indiana Capital Chronicle)
Hundreds of Hoosiers die each year in traffic collisions and thousands more are seriously injured. Numbers have fallen slightly but Indiana traffic safety groups are working to bring that number down even further statewide.
According to the Indiana Criminal Justice Institute, traffic fatalities decreased to 894 in 2023 compared to 985 fatalities in 2022. Another 4,232 Hoosiers were seriously injured in traffic crashes in 2023 while 5443 were seriously injured in traffic crashes in 2022.
Indianapolis-based nonprofit Health by Design is partnering with the Institute to expand its Indiana Road to Zero Academy, aiming to reduce serious traffic crashes and fatalities across the state.
Solutions include tactical urbanism, which uses street murals, separators and pedestrian-only lanes to slow down traffic and accommodate bikes, wheelchairs and strollers.
'Streets need to be rebuilt every year,' said Andrea Watts, Health by Design's communications and policy manager. 'We want to rebuild them right, but not just car orientated infrastructure — safe streets for everyone.'
Launched in 2022 with funding from the National Safety Council and Road to Zero Coalition, the academy initially offered virtual training over several weeks, spreading awareness and knowledge to various stakeholders working to improve Indiana's roadway. Now backed by the Indiana Criminal Justice Institute Traffic Safety Improvement Program, the program is shifting gears.
The Indiana Road to Zero Academy plans to offer two in-person regional training workshops — one in northern Indiana and one in southern Indiana — in mid- or late September. These hands-on sessions will teach the safe system approach: safe roads, safe speeds, and safe road users. It is designed for municipal staff, planners, engineers, safety advocates, and residents.
'Northern and southern Indiana were hungry to get this rolling,' Watts said.
The expanded academy also introduces a statewide Vision Zero Working Group, building on the Indianapolis Vision Zero Ordinance adopted in August 2024. Vision Zero prioritizes eliminating traffic deaths and serious injuries through smarter road designs that ensure safe travel for pedestrians, cyclists and drivers alike.
Health by Design will provide customized crash analysis and technical assistance to high-risk areas, partnering with data experts and EMS records to track fatal crashes and identify solutions.
The group has also teamed up with the Indiana Department of Transportation and the Department of Health to improve community safety. One of their initiatives, the Safe Routes to School program, is open to all Indiana schools — regardless of federal funding — and encourages more students to walk or bike safely to class.
Through this program, the organization supports schools through grants such as one for bike helmets. Most recently, they supported Fort Wayne students participating in Bike-to-School Day, Watts said.
Despite challenges from recent federal funding cuts and changes, the organization remains committed to enhancing traffic safety. Proposed federal funding cuts on green infrastructure attacks a lot of the work the nonprofit does, Watts said. Following threats to federal funding, state partnerships are becoming even more important.
'It has impacted us and we had to get more creative,' Watts said. 'There's an attack on a lot of the work we do and it feels like a step backward or we are stuck in time.'
SUBSCRIBE: GET THE MORNING HEADLINES DELIVERED TO YOUR INBOX
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
3 hours ago
- The Hill
US warns of ‘heightened threat environment' after strikes on Iran
The United States is warning of a 'heightened threat environment' after President Trump ordered strikes on three Iranian nuclear sites on Saturday evening. The Department of Homeland Security (DHS) issued a National Terrorism Advisory System (NTAS) bulletin on Sunday, alerting the public to the potential of cyberattacks carried out by those who support Iran or are affiliated with the Iranian government. 'The ongoing Iran conflict is causing a heightened threat environment in the United States. Low-level cyber attacks against US networks by pro-Iranian hacktivists are likely, and cyber actors affiliated with the Iranian government may conduct attacks against US networks,' the bulletin read. The bulletin also noted that the Iranian government, in recent years, has sought to target U.S. government officials it deems responsible for killing the former Iranian military officer, Qasem Soleimani. 'The likelihood of violent extremists in the Homeland independently mobilizing to violence in response to the conflict would likely increase if Iranian leadership issued a religious ruling calling for retaliatory violence against targets in the Homeland,' the bulletin read. The bulletin warned that the ongoing conflict 'could contribute to US-based individuals plotting additional attacks' on U.S. soil that are 'motivated by anti-Semitic or anti-Israel sentiment.' 'It is our duty to keep the nation safe and informed, especially during times of conflict. The ongoing Israel-Iran conflict brings the possibility of increased threat to the homeland in the form of possible cyberattacks, acts of violence, and antisemitic hate crimes,' DHS Secretary Kristi Noem said in a statement to The Hill. Trump announced Saturday evening that U.S. forces bombed three Iranian nuclear sites and said to Iran in a social media post, 'NOW IS THE TIME FOR PEACE!' The bombs targeted three nuclear sites in Natanz, Esfahan and Fordow, located inside a mountain. Six 'bunker buster' bombs were reportedly dropped on Fordow, while more than two dozen Tomahawk missiles were launched at the other two sites. The bombings put the U.S. directly in Iran's crosshairs for retaliation and made it an active participant in the Mideast war, which Israel launched with airstrikes against Iran on June 13.
Yahoo
4 hours ago
- Yahoo
Lilly's once-weekly insulin efsitora alfa demonstrated A1C reduction and a safety profile consistent with daily insulin in multiple Phase 3 trials
Results from the fixed-dose QWINT-1 study, along with the QWINT-3 and QWINT-4 studies, reinforce efsitora's potential to simplify insulin management with weekly dosing Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year INDIANAPOLIS, June 22, 2025 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced detailed results from QWINT-1, QWINT-3, and QWINT-4 Phase 3 clinical trials evaluating the safety and efficacy of investigational once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes who used insulin for the first time, previously used daily basal insulin, and previously used daily basal insulin and mealtime insulin, respectively. In each trial, once-weekly efsitora met the primary endpoint of non-inferior A1C reduction compared to daily basal insulin. The complete results from these studies were presented at the American Diabetes Association (ADA) 85th Scientific Sessions 2025. Simultaneously, results from QWINT-1, a first-of-its-kind fixed-dose study, were published in The New England Journal of Medicine, while results from QWINT-3 and QWINT-4 were published in The Lancet. In QWINT-1, efsitora reduced A1C by 1.31% compared to 1.27% for insulin glargine at week 52 for the efficacy estimand.1,2 In the trial, efsitora was titrated to four fixed doses at four-week intervals, as needed for blood glucose control.3 In QWINT-3, efsitora reduced A1C by 0.86% compared to 0.75% for insulin degludec at week 26 for the efficacy estimand.4 In QWINT-4, efsitora reduced A1C by 1.07% compared to 1.07% for insulin glargine at week 26 for the efficacy estimand.5 In these two trials, efsitora was administered using traditional insulin dosing with adjustments based on each patient's glucose level. "The novel fixed-dose regimen used in QWINT-1 for once-weekly efsitora, which consisted of only four single-dose titration options, has the potential to facilitate and simplify insulin therapy, reducing the hesitation often associated with starting insulin to treat type 2 diabetes," said Dr. Julio Rosenstock, senior scientific advisor for Velocity Clinical Research at Medical City Dallas, clinical professor of medicine, University of Texas Southwestern Medical Center, and lead trial investigator for QWINT-1. "A simpler, once-weekly regimen with efsitora may help people with type 2 diabetes initiate and manage insulin therapy with the goal of improving blood sugar levels. Across all QWINT trials, the results showed that once-weekly efsitora controlled glucose as effectively as the most popular once-daily basal insulins." QWINT-1 Primary EndpointEfficacy Estimand Treatment-RegimenEstimand6 Primary Endpoint – A1C Reduction (Resulting A1C) at Week 52 Efsitora -1.31 % (6.92 %) -1.19 % (7.05 %) Glargine -1.27 % (6.96 %) -1.16 % (7.08 %)QWINT-3 Primary and Key Secondary EndpointsEfficacy Estimand Treatment-RegimenEstimand Primary Endpoint – A1C Reduction (Resulting A1C) at Week 26 Efsitora -0.86 % (6.93 %) -0.81 % (6.99 %) Degludec -0.75 % (7.03 %) -0.72 % (7.08 %) Key Secondary Endpoint – Rates of Clinically Significant or Severe Nocturnal Hypoglycemic Events Per Patient-Year of Exposure up to Week 787,8 Efsitora 0.11 Degludec 0.10 Key Secondary Endpoint – Percent Time in Range (70-180 mg/dL) During the FourWeeks Prior to Week 26 Efsitora 62.8 % 61.4 % Degludec 61.3 % 61.0 %QWINT-4 Primary and Key Secondary EndpointsEfficacy Estimand Treatment-Regimen Estimand Primary Endpoint – A1C Reduction (Resulting A1C) at Week 26 Efsitora -1.07 % (7.12 %) -1.01 % (7.17 %) Glargine -1.07 % (7.11 %) -1.00 % (7.18 %) Key Secondary Endpoint – Participants Achieving A1C <7% at Week 26 Without Nocturnal Hypoglycemia Efsitora 39.5 % 38.6 % Glargine 36.6 % 35.9 % Key Secondary Endpoint – Rates of Clinically Significant or Severe NocturnalHypoglycemic Events Per Patient-Year of Exposure up to Week 26 Efsitora 0.67 Glargine 1.00 "Building on Lilly's legacy of innovation in insulin therapy, once-weekly efsitora may offer a significant advancement for people with type 2 diabetes who need insulin by eliminating over 300 injections per year," said Jeff Emmick, M.D., Ph.D., senior vice president of product development at Lilly. "These results reinforce the potential for once-weekly efsitora to help reduce the overall burden of insulin therapy through a simplified treatment approach. We look forward to working with regulatory agencies to bring this innovation to patients around the world." Across the three trials, efsitora demonstrated an overall safety profile similar to two of the most commonly used daily basal insulin therapies for the treatment of type 2 diabetes. In QWINT-1, efsitora resulted in approximately 40% fewer hypoglycemic events compared to insulin glargine, with estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure of 0.50 with efsitora vs. 0.88 with insulin glargine at 52 weeks. In QWINT-3, these rates were 0.84 with efsitora vs. 0.74 with insulin degludec at 78 weeks. In QWINT-4, estimated combined rates of severe or clinically significant hypoglycemic events per patient-year of exposure were 6.6 with efsitora vs. 5.9 with insulin glargine at 26 weeks. Lilly plans to submit efsitora for the treatment of adults with type 2 diabetes to global regulatory agencies by the end of this year. About the QWINT clinical trial programThe QWINT Phase 3 global clinical development program for insulin efsitora alfa (efsitora) in diabetes began in 2022 and has enrolled more than 3,000 people living with type 2 diabetes across four global registration studies. QWINT-1 (NCT05662332) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin using a fixed dose escalation to daily insulin glargine for 52 weeks in insulin-naïve adults with type 2 diabetes. The trial randomized 795 participants across the U.S., Argentina and Mexico to receive efsitora once weekly or insulin glargine once daily, administered subcutaneously. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 52 with efsitora compared to daily use of insulin glargine. QWINT-3 (NCT05275400) was a multicenter, randomized, parallel-design, open-label trial comparing the efficacy and safety of efsitora as a once-weekly basal insulin to insulin degludec for 78 weeks after a three-week lead-in followed by a five-week safety follow up period, in adults with type 2 diabetes who are currently treated with basal insulin. The trial randomized 986 participants across the U.S., Argentina, Hungary, Japan, Korea, Poland, Puerto Rico, Slovakia, Spain and Taiwan to receive efsitora once weekly or insulin degludec once daily, administered subcutaneously. The primary objective of the study was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin degludec. QWINT-4 (NCT05462756) was a parallel-design, open-label, treat-to-target, randomized controlled clinical trial comparing the efficacy and safety of efsitora as a weekly basal insulin to insulin glargine for 26 weeks in adults with type 2 diabetes who have previously been treated with basal insulin and at least two injections per day of mealtime insulin. The trial randomized 730 participants across the U.S., Argentina, Germany, India, Italy, Mexico, Puerto Rico and Spain to receive efsitora once weekly or insulin glargine once daily, both of which were administered subcutaneously along with insulin lispro. The primary objective of the trial was to demonstrate non-inferiority in reducing A1C at week 26 with efsitora compared to insulin glargine. About insulin efsitora alfaInsulin efsitora alfa (efsitora) is a once-weekly basal insulin, a fusion protein that combines a novel single-chain variant of insulin with a human IgG2 Fc domain. It is specifically designed for once-weekly subcutaneous administration, and with its low peak-to-trough ratio, it has the potential to provide more stable glucose levels (less glucose variability) throughout the week. About Lilly Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit and or follow us on Facebook, Instagram, and LinkedIn. P-LLY The efficacy estimand represents the treatment effect on all participants who adhered to the study drug without initiating rescue therapy for persistent severe hyperglycemia. From a baseline of 8.20% for efsitora and 8.28% for insulin glargine. Participants treated with efsitora received a starting dose of 100 units of insulin, followed by escalation to fixed dosages of 150 units, 250 units and 400 units every four weeks, as needed, until achieving a target fasting blood glucose of 80-130 mg/dL. Participants with fasting blood glucose greater than 130 mg/dL on or after 16 weeks were transferred to flexible dosing. From a baseline of 7.80% for both efsitora and insulin degludec. From a baseline of 8.18% for both efsitora and insulin glargine. The treatment-regimen estimand represents the estimated average treatment effect regardless of treatment discontinuation or introduction of rescue therapy for persistent severe hyperglycemia. Blood glucose <54 mg/dL. Nocturnal hypoglycemia was defined as any event that occurred at night between midnight and 6 a.m. Cautionary Statement Regarding Forward-Looking StatementsThis press release contains forward-looking statements (as that term is defined in the Private Securities Litigation Reform Act of 1995) about insulin efsitora alfa as a potential treatment for people with type 2 diabetes and the timeline for future readouts, presentations, and other milestones relating to insulin efsitora alfa and its clinical trials and reflects Lilly's current beliefs and expectations. However, as with any pharmaceutical product, there are substantial risks and uncertainties in the process of drug research, development, and commercialization. Among other things, there is no guarantee that future study results will be consistent with study results to date, that insulin efsitora alfa will prove to be a safe and effective treatment for type 2 diabetes, that insulin efsitora alfa will receive regulatory approval, or that Lilly will execute its strategy as expected. For further discussion of these and other risks and uncertainties that could cause actual results to differ from Lilly's expectations, see Lilly's Form 10-K and Form 10-Q filings with the United States Securities and Exchange Commission. Except as required by law, Lilly undertakes no duty to update forward-looking statements to reflect events after the date of this release. Trademarks and Trade NamesAll trademarks or trade names referred to in this press release are the property of the company, or, to the extent trademarks or trade names belonging to other companies are referenced in this press release, the property of their respective owners. Solely for convenience, the trademarks and trade names in this press release are referred to without the ® and ™ symbols, but such references should not be construed as any indicator that the company or, to the extent applicable, their respective owners will not assert, to the fullest extent under applicable law, the company's or their rights thereto. We do not intend the use or display of other companies' trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies. Refer to: Niki Biro; niki_biro@ 317-358-9074 (Media)Michael Czapar; czapar_michael_c@ 317-617-0983 (Investors) View original content to download multimedia: SOURCE Eli Lilly and Company Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Miami Herald
5 hours ago
- Miami Herald
Satellite images undermine Trump's claim atomic sites destroyed
President Donald Trump's decision to order U.S. forces to attack three key Iranian nuclear installations may have sabotaged the Islamic Republic's known atomic capabilities, but it's also created a monumental new challenge to work out what's left and where. Trump said heavily fortified sites were "totally obliterated" late Saturday, but independent analysis has yet to verify that claim. Rather than yielding a quick win, the strikes have complicated the task of tracking uranium and ensuring Iran doesn't build a weapon, according to three people who follow the country's nuclear program. International Atomic Energy Agency monitors remain in Iran and were inspecting more than one site a day before Israel started the bombing campaign on June 13. They are still trying to assess the extent of damage, and while military action might be able to destroy Iran's declared facilities, it also provides an incentive for Iran to take its program underground. Trump dispatched B-2 stealth jets laden with Massive Ordnance Penetrators, known as GBU-57 bombs, to attempt to destroy Iran's underground uranium-enrichment sites in Natanz and Fordow. Satellite images taken on Sunday of Fordow and distributed by Maxar Technologies show new craters, possible collapsed tunnel entrances and holes on top of a mountain ridge. They also show that a large support building on the Fordow site, which operators may use to control ventilation for the underground enrichment halls, remained undamaged. There were no radiation releases from the site, the IAEA reported. U.S. Air Force General Dan Caine told a news conference on Sunday that an assessment of "final battle damage will take some time." IAEA inspectors, meanwhile, haven't been able to verify the location of the Persian Gulf country's stockpile of near-bomb-grade uranium for more than a week. Iranian officials acknowledged breaking IAEA seals and moving it to an undisclosed location. Indeed, there's just a slim possibility that the U.S. entering the war will convince Iran to increase IAEA cooperation, said Darya Dolzikova, a senior research fellow at the Royal United Services Institute, a London-based think tank. "The more likely scenario is that they convince Iran that cooperation and transparency don't work and that building deeper facilities and ones not declared openly is more sensible to avoid similar targeting in future," she said. The IAEA called on a cessation of hostilities in order to address the situation. Its 35-nation board will convene on Monday in Vienna, Director General Rafael Mariano Grossi said. Before the U.S. intervention, images showed Israeli forces alone had met with limited success four days after the bombing began. Damage to the central facility in Natanz, located 300 kilometers (186 miles) south of Tehran, was primarily limited to electricity switch yards and transformers. The U.S. also joined in attacking the Isfahan Nuclear Technology and Research Center, located 450 kilometers south of Tehran. That was after the IAEA re-assessed the level of damage Israel had dealt to facility. Based on satellite images and communications with Iranian counterparts Isfahan appeared "extensively damaged," the agency wrote late on Saturday. The IAEA's central mission is to account for gram-levels of uranium around the world and to ensure it isn't used for nuclear weapons. The latest bombing now complicates tracking Iranian uranium even further, said Tariq Rauf, the former head of the IAEA's nuclear-verification policy. "It will now be very difficult for the IAEA to establish a material balance for the nearly 9,000 kilograms of enriched uranium, especially the nearly 410 kilograms of 60% enriched uranium," he said. Last week, inspectors had already acknowledged they'd lost track of the location of Iran's highly enriched uranium stockpile because Israel's ongoing military assaults are preventing its inspectors from doing their work. That uranium inventory - enough to make 10 nuclear warheads at a clandestine location - was seen at Isfahan by IAEA inspectors. But the material, which could fit in as few as 16 small containers, may have already been spirited off site. "Questions remain as to where Iran may be storing its already enriched stocks," Dozikova said. "These will have almost certainly been moved to hardened and undisclosed locations, out of the way of potential Israeli or U.S. strikes." Far from being just static points on a map, Iran's ambitions to make the fuel needed for nuclear power plants and weapons are embedded in a heavily fortified infrastructure nationwide. Thousands of scientists and engineers work at dozens of sites. Even as military analysts await new satellite images before determining the success of Trump's mission, nuclear safeguards analysts have reached the conclusion that their work is about to become significantly harder. By bombing Iran's sites, Israel and the U.S. haven't just disrupted the IAEA's accountancy of Iran's nuclear stockpile, they've also degraded the tools that monitors will be able to use, said Robert Kelley, who led inspections of Iraq and Libya as an IAEA director. That includes the forensic method used to detect the potential diversion of uranium. "Now that sites have been bombed and all classes of materials have been scattered everywhere the IAEA will never again be able to use environmental sampling," he said. "Particles of every isotopic description have infinite half-lives for forensic purposes and it will be impossible to sort out their origin." _____ Copyright (C) 2025, Tribune Content Agency, LLC. Portions copyrighted by the respective providers.
